US FDA Classifies Recall Of Philips’ Respiratory Devices As Most Serious

Maryland (Reuters) The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of Dutch medical devices maker Philips’ respiratory machines as most serious, saying their use could lead to injuries or death.

The U.S. health regulator said the silicon foam used in some reworked ventilator models may separate from plastic backing due to adhesive failure and can reduce the air flow as well as cause debris contamination.

The company’s ventilators provide breathing assistance to both pediatric and adult patients.

The recall follows Philips’ move to call back millions of breathing devices and ventilators in June 2021 due to the potential of a foam part degrading and becoming toxic, possibly causing cancer.

Its subsidiary, Philips Respironics, had in December also recalled about 13,811 ventilators which were distributed between March 1, 2022 and Sept. 6, 2022.

Philips did not immediately respond to a Reuters request for comment on the impact from the recall.

There were 82 complaints till Jan. 4 and no reports of death or long-term injuries associated with the use of the product, the U.S. FDA said.

  • Related Posts

    Unapproved drops for dry eyes pose risks: Govt

    NEW DELHI: Flagging that certain yet-to-be-approved dry eye relief drops are being sold in the market, the central drugs regulator has asked states to cancel any permissions granted for these…

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Unapproved drops for dry eyes pose risks: Govt

    Unapproved drops for dry eyes pose risks: Govt

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Govt highlights multi-layer framework to curb misleading advertisements

    Govt highlights multi-layer framework to curb misleading advertisements

    Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

    Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

    Study finds rising resistance to a last-resort antibiotic in Africa

    Study finds rising resistance to a last-resort antibiotic in Africa